Red X iconGreen tick iconYellow tick icon

Barry HockScientific Officer
Honorary Research Fellow

BSc(Hons), PhD(Otago)

Email barry.hock@otago.ac.nz
Tel 64 3 364 0579

Publications

Barclay, M. L., Keating, P. E., Hock, B. D., Chin, P. K. L., & O'Donnell, J. L. (2023). Infliximab or adalimumab antidrug-antibody complex size has more clinical value than concentration. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting: Transformational Pharmacology and Toxicology. 235. Retrieved from https://www.asceptasm.com Conference Contribution - Published proceedings: Abstract

Barclay, M. L., Keating, P. E., Hock, B. D., Smith, S. M., Chin, P. K. L., & O'Donnell, J. L. (2023). Four-year review of New Zealand laboratory infliximab and adalimumab concentration results indicating high potential for improved dosing. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting: Transformational Pharmacology and Toxicology. P513. Retrieved from https://www.asceptasm.com Conference Contribution - Published proceedings: Abstract

Keating, P. E., Hock, B. D., Smith, S. M., Chin, P. K. L., O'Donnell, J. L., & Barclay, M. L. (2023). Four-year review of New Zealand laboratory infliximab and adalimumab concentration results indicating potential for improved dosing [Brief communication]. Internal Medicine Journal, 53(11), 2123-2127. doi: 10.1111/imj.16264 Journal - Research Other

Hock, B. D., Goddard, L., MacPherson, S. A., Strother, M., Gibbs, D., Pearson, J. F., & McKenzie, J. L. (2023). Levels and in vitro functional effects of circulating anti-hinge antibodies in melanoma patients receiving the immune checkpoint inhibitor pembrolizumab. PLoS ONE, 18(9), e0290793. doi: 10.1371/journal.pone.0290793 Journal - Research Article

Sulit, A. K., Daigneault, M., Allen-Vercoe, E., Silander, O. K., Hock, B., McKenzie, J., Pearson, J., Frizelle, F. A., Schmeier, S., & Purcell, R. (2023). Bacterial lipopolysaccharide modulates immune response in the colorectal tumor microenvironment. npj Biofilms & Microbiomes, 9, 59. doi: 10.1038/s41522-023-00429-w Journal - Research Article

Back to top